In a report issued on January 20, Inigo Egusquiza from Kepler Capital maintained a Hold rating on Grifols SA (GRFS), with a price target of EUR28.30. The company’s shares closed last Thursday at $19.33.
According to TipRanks.com, Egusquiza is a 3-star analyst with an average return of 1.8% and a 50.7% success rate. Egusquiza covers the Services sector, focusing on stocks such as DO & CO Aktiengesellschaft, Mediaset España, and Vivendi.
Currently, the analyst consensus on Grifols SA is a Moderate Buy with an average price target of $34.27.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.73 and a one-year low of $13.40. Currently, Grifols SA has an average volume of 855.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
